Marshall Wace’s Novavax NVAX Stock Holding History

Marshall Wace’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$814	Sell	100 -300	-75%	-$2.72K	﹤0.01%	3128
2025 Q4	$2.69K	Sell	400 -600	-60%	-$4.52K	﹤0.01%	2890
2025 Q3	$8.67K	Buy	+1,000	New	+$7.78K	﹤0.01%	2810

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's NVAX Position: Q1 2026 in Review

Marshall Wace increased its Novavax (NVAX) stake by 25% in Q1 2026, buying an estimated $2.14M and bringing the position to 1,166,197 shares worth $9.49M. The position accounts for 0.01% of the portfolio, ranked #1002.

Marshall Wace first reported a position in NVAX in Q4 2020 and has held it in 12 quarters since. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Marshall Wace held 1,166,197 shares of Novavax worth $9.49M as of Q1 2026.
Marshall Wace bought 236,586 Novavax shares in Q1 2026, an estimated $2.14M.
Novavax made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1002 holding.
Marshall Wace first reported a position in Novavax in Q4 2020 and has held it in 12 quarters since.
257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.